Year: 2021

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer, today announced that human preclinical data will be presented demonstrating that enobosarm treatment alone as well as in combination with a CDK4/6 inhibitor increased androgen receptor (AR) expression resulting in the synergistic suppression of breast cancer cell and tumor models that are resistant to CDK4/6 inhibitors and estrogen blocking agents. Enobosarm is an oral, first-in-class, selective androgen receptor targeted agonist for the androgen receptor, a tumor suppressor, being evaluated in Phase 3 clinical studies to treat AR+ER+HER2- metastatic breast cancer without unwanted masculinizing side effects. The presentation was...

WorksportGlobal Original Equipment ManufacturerMississauga, Dec. 08, 2021 (GLOBE NEWSWIRE) — Worksport Ltd (Nasdaq: WKSP) (the “Company”) continues its plan to become a global original equipment manufacturer (OEM). After a solid year of building, strategizing, and operational change management, the Company started due diligence on potential automotive manufacturers as of third quarter this year – – to actively seek out partners interested in solar integration programs. Through active efforts, the Company is currently engaged in discussions with several global automotive manufacturers for OEM contracts. The Company believes that its new strategy of growth through obtaining OEM contracts will increase value for the Company’s shareholders. If Worksport succeeds in assuming the position of a major OEM,...

SAINT LAURENT, Quebec, Dec. 08, 2021 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that it has initiated an arbitration proceeding against Tilray, Inc. (“Tilray®”) related to an alleged breach of the parties’ 2018 license, development and supply agreement, as amended (the “Agreement”), with Tilray® for the co-development and commercialization of cannabis-infused VersaFilm® products. The action follows a recent press release issued by Tilray® announcing its launch of medical cannabis oral strips in THC and CBD-rich varieties based on a competitive oral thin film technology to IntelGenx’s VersaFilm® platform. IntelGenx believes this represents a material breach of the Agreement. “We believe that this demonstrates a disregard of contractual obligations...

DAVIDsTEA x BetterSleepDAVIDsTEA Partners with BetterSleep App to Support the Connection Between Tea and Healthy SleepMONTRÉAL, Dec. 08, 2021 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (Nasdaq:DTEA), a leading tea merchant in North America, is pleased to announce a new partnership with wellness and sleep tracking app BetterSleep (formerly Relax Melodies), uniquely designed to help people stress less, and sleep better. “DAVIDsTEA has always had great success with sleep and relaxation blends and infusions, and the partnership we’re announcing today with BetterSleep helps to bring this expertise, one step further,” said Sarah Segal, Chief Executive Officer and Chief Brand Officer, DAVIDsTEA. “More than ever, people are willing and eager to make simple but meaningful changes to their daily routines to improve their overall...

Estimated peak potential revenue for MBI-306 and its variants is $100 million DAVIS, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) — Field trials in 2021 for Marrone Bio Innovations’ (NASDAQ: MBII) next-generation product for environmentally sustainable control of yield-robbing pests in corn and soybeans demonstrated excellent efficacy with substantial yield gains at reduced application rates. “MBI-306 continues to demonstrate the benefits that farmers and consumers desire in healthier foods grown with a lighter environmental footprint,” said Marrone Bio’s Chief Executive Officer Kevin Helash. “This second-generation product offers growers a more sustainable solution to controlling pests with better yields. Additionally, with a reduced application rate, MBI-306 will be even more competitive against leading synthetic standards in terms...

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has extended the expiration of its previously announced tender offer for shares of its common stock from one minute after 11:59 P.M., New York City time, on December 7, 2021 until one minute after 11:59 P.M., New York City time, on December 15, 2021 (unless further extended or earlier terminated). Based on information provided by Continental Stock Transfer & Trust Company, the depositary for the tender offer, to date, 8,282,336 shares have been tendered for purchase in the tender offer. Stockholders who have validly...

– COVID-19 Consumer Health Communications Campaign won silver in the “Mobile Digital Health Resources: Text Messaging” category– TelaRep Interactive EHR Communication received a merit award in the “Connected Digital Health: Clinical Decision Support Tools” category ROCHESTER, Mich., Dec. 08, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that it has earned Digital Health Awards’ silver award for the Company’s COVID-19 Consumer Health Communications Campaign, and a merit award for its TelaRep Clinical Decision Support Tool. Will Febbo, OptimizeRx’s CEO, commented, “We are grateful for the industry recognition of our innovative platform technology solutions and their various applications....

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that Rob Kelley, the Company’s current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately. Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters. About Rob KelleyMr. Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Company’s Chief Commercial Officer since September 2020. Before Talis, Mr. Kelley was Vice President, Sales and Commercial Development of Genalyte, Inc., a healthcare...

FALLS CHURCH, Va., Dec. 08, 2021 (GLOBE NEWSWIRE) — PAE (NASDAQ: PAE, PAEWW), a global leader in delivering smart solutions to the U.S. government and its allies, announced today it has achieved two certifications through the International Organization for Standardization, or ISO. PAE now holds certifications for ISO 45001:2018, Occupational Health and Safety Management Systems, and ISO 14001:2015, Environmental Management Systems. PAE Interim President and CEO Charlie Peiffer said the ISO certifications are the culmination of hard work by stakeholders across the organization, led by the PAE Occupational Health, Environment and Safety team through its Ready, Set, Protect initiative. “For 2021, we set a strategic goal of meeting these standards and certifying related corporate operations as a process improvement and to show the...

FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appointed six new key opinion leaders (KOLs) across retina, refractive surgery, and optometry to its Medical Advisory Board (MAB). “The opportunity to assemble such a dynamic and admired roster of medical advisors is exciting and will certainly broaden Ocuphire’s potential,” said Mina Sooch, Founder and CEO of Ocuphire Pharma. “In the medical community, their clinical expertise and knowledge of ophthalmic drug development have earned them global distinction as key thought-leaders, panelists, authors, clinical investigators, and commercial...